Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Repligen Cp 41 SEYON STREET BUILDING 1 SUITE 100 WALTHAM MA 02453 USA

www.repligen.com P: 781-250-0111 F: 781-250-0115

Description:

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.

Key Statistics

Overview:

Market Capitalization, $K 9,250,289
Enterprise Value, $K 8,568,419
Shares Outstanding, K 55,839
Annual Sales, $ 638,760 K
Annual Net Income, $ 41,580 K
Last Quarter Sales, $ 155,740 K
Last Quarter Net Income, $ -25,490 K
EBIT, $ 54,580 K
EBITDA, $ 125,110 K
60-Month Beta 1.02
% of Insider Shareholders 1.20%
% of Institutional Shareholders 97.64%
Float, K 55,169
% Float 98.80%
Short Volume Ratio 0.70

Growth:

1-Year Return 12.48%
3-Year Return -21.75%
5-Year Return 145.06%
5-Year Revenue Growth 229.21%
5-Year Earnings Growth 139.73%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.33 on 02/21/24
Latest Earnings Date 05/01/24 [BMO]
Earnings Per Share ttm 1.73
EPS Growth vs. Prev Qtr 43.48%
EPS Growth vs. Prev Year -51.47%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RGEN Ratios

Ratio
Price/Earnings ttm 97.03
Price/Earnings forward 117.68
Price/Earnings to Growth 5.61
Return-on-Equity % 5.00%
Return-on-Assets % 3.78%
Profit Margin % 6.51%
Debt/Equity 0.04
Price/Sales 14.67
Price/Cash Flow 56.61
Price/Book 4.85
Book Value/Share 35.31
Interest Coverage 33.89
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar